NO20091530L - Fenylalkylaminokarbamat preparater - Google Patents

Fenylalkylaminokarbamat preparater

Info

Publication number
NO20091530L
NO20091530L NO20091530A NO20091530A NO20091530L NO 20091530 L NO20091530 L NO 20091530L NO 20091530 A NO20091530 A NO 20091530A NO 20091530 A NO20091530 A NO 20091530A NO 20091530 L NO20091530 L NO 20091530L
Authority
NO
Norway
Prior art keywords
phenylalkylaminocarbamate
preparations
compound
composition
admixture
Prior art date
Application number
NO20091530A
Other languages
English (en)
Inventor
Ramendra N Pandey
Tracey Mascaro
Stanley Altan
Aniruddha M Railkar
James Mccool
Hinton Clark
Original Assignee
Janssen Pharmaceutica Nv
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Janssen Pharmaceutica Nv filed Critical Janssen Pharmaceutica Nv
Publication of NO20091530L publication Critical patent/NO20091530L/no

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/325—Carbamic acids; Thiocarbamic acids; Anhydrides or salts thereof
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/02—Inorganic compounds
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/20—Pills, tablets, discs, rods
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/20—Pills, tablets, discs, rods
    • A61K9/2004—Excipients; Inactive ingredients
    • A61K9/2009—Inorganic compounds
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/20—Pills, tablets, discs, rods
    • A61K9/2004—Excipients; Inactive ingredients
    • A61K9/2013—Organic compounds, e.g. phospholipids, fats
    • A61K9/2018—Sugars, or sugar alcohols, e.g. lactose, mannitol; Derivatives thereof, e.g. polysorbates
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P21/00—Drugs for disorders of the muscular or neuromuscular system
    • A61P21/02—Muscle relaxants, e.g. for tetanus or cramps
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/02—Drugs for disorders of the nervous system for peripheral neuropathies
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/04—Centrally acting analgesics, e.g. opioids
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/06—Antimigraine agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/08—Antiepileptics; Anticonvulsants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/14—Drugs for disorders of the nervous system for treating abnormal movements, e.g. chorea, dyskinesia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/14—Drugs for disorders of the nervous system for treating abnormal movements, e.g. chorea, dyskinesia
    • A61P25/16—Anti-Parkinson drugs
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/18—Antipsychotics, i.e. neuroleptics; Drugs for mania or schizophrenia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/22—Anxiolytics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/24—Antidepressants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/30—Drugs for disorders of the nervous system for treating abuse or dependence
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • General Health & Medical Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Medicinal Chemistry (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Neurology (AREA)
  • General Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Biomedical Technology (AREA)
  • Neurosurgery (AREA)
  • Epidemiology (AREA)
  • Pain & Pain Management (AREA)
  • Psychiatry (AREA)
  • Inorganic Chemistry (AREA)
  • Molecular Biology (AREA)
  • Biophysics (AREA)
  • Psychology (AREA)
  • Hospice & Palliative Care (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Urology & Nephrology (AREA)
  • Vascular Medicine (AREA)
  • Cardiology (AREA)
  • Orthopedic Medicine & Surgery (AREA)
  • Physical Education & Sports Medicine (AREA)
  • Addiction (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Medicinal Preparation (AREA)
  • Organic Low-Molecular-Weight Compounds And Preparation Thereof (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Agricultural Chemicals And Associated Chemicals (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)

Abstract

Det beskrives et preparat av en fenylalkylaminokarbamatforbindelse som resulterer i forbedret stabilitet, der preparatet omfatter en fenylalkylaminokarbamatforbindelse i blanding med en effektiv mengde av en eller flere eksipienser der minst én eksipient er dibasisk kalsiumfosfatdihydrat.
NO20091530A 2006-10-13 2009-04-17 Fenylalkylaminokarbamat preparater NO20091530L (no)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US82934206P 2006-10-13 2006-10-13
PCT/US2007/080675 WO2008048801A2 (en) 2006-10-13 2007-10-08 Phenylalkylamino carbamate compositions

Publications (1)

Publication Number Publication Date
NO20091530L true NO20091530L (no) 2009-07-06

Family

ID=39111348

Family Applications (1)

Application Number Title Priority Date Filing Date
NO20091530A NO20091530L (no) 2006-10-13 2009-04-17 Fenylalkylaminokarbamat preparater

Country Status (19)

Country Link
US (1) US20080090902A1 (no)
EP (1) EP2079449A2 (no)
JP (1) JP2010506845A (no)
KR (1) KR20090082213A (no)
CN (1) CN101557804A (no)
AU (1) AU2007313017A1 (no)
BR (1) BRPI0719275A2 (no)
CA (1) CA2673487A1 (no)
CO (1) CO6180500A2 (no)
CR (1) CR10794A (no)
EA (1) EA200970377A1 (no)
GT (1) GT200900082A (no)
IL (1) IL198145A0 (no)
MX (1) MX2009003926A (no)
NI (1) NI200900053A (no)
NO (1) NO20091530L (no)
SV (1) SV2009003221A (no)
WO (1) WO2008048801A2 (no)
ZA (1) ZA200903283B (no)

Families Citing this family (15)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CA2611713C (en) 2005-06-08 2013-10-01 Sk Holdings Co., Ltd. Treatment of sleep-wake disorders
AU2010270971B2 (en) 2009-06-22 2015-08-20 Sk Biopharmaceuticals Co., Ltd. Methods for treating or preventing fatigue
MX350745B (es) 2009-11-06 2017-09-14 Sk Biopharmaceuticals Co Ltd * El uso de un compuesto de carbamoilo para el tratamiento del sindrome de fibromialgia.
US8895609B2 (en) 2009-11-06 2014-11-25 Sk Biopharmaceuticals Co., Ltd. Methods for treating attention-deficit/hyperactivity disorder
US9610274B2 (en) 2010-06-30 2017-04-04 Sk Biopharmaceuticals Co., Ltd. Methods for treating bipolar disorder
US8623913B2 (en) * 2010-06-30 2014-01-07 Sk Biopharmaceuticals Co., Ltd. Methods for treating restless legs syndrome
EP2970109A4 (en) * 2013-03-12 2017-01-18 Bio-Pharm Solutions Co., Ltd. Phenyl carbamate compound and a composition for neuroprotection comprising the same
KR101717872B1 (ko) 2013-03-12 2017-03-17 (주)바이오팜솔루션즈 소아 간질 및 간질-관련 증후군의 예방 또는 치료용 페닐카바메이트 화합물
TWI684450B (zh) 2013-03-13 2020-02-11 南韓商愛思開生物製藥股份有限公司 猝倒症之治療
WO2015010014A1 (en) 2013-07-18 2015-01-22 Jazz Pharmaceuticals International Iii Limited Treatment for obesity
US10195151B2 (en) 2016-09-06 2019-02-05 Jazz Pharmaceuticals International Iii Limited Formulations of (R)-2-amino-3-phenylpropyl carbamate
KR20230145525A (ko) 2017-06-02 2023-10-17 재즈 파마슈티칼즈 아일랜드 리미티드 과다 졸림증을 치료하기 위한 방법 및 조성물
CN110037995B (zh) * 2019-04-17 2021-07-06 石家庄龙泽制药股份有限公司 一种稳定的盐酸帕罗西汀片剂及其制备方法
US10940133B1 (en) 2020-03-19 2021-03-09 Jazz Pharmaceuticals Ireland Limited Methods of providing solriamfetol therapy to subjects with impaired renal function
IT202000013855A1 (it) 2020-06-10 2021-12-10 Flamma Spa Un processo per la purificazione del (r)-2-ammino-3-fenilpropil carbammato

Family Cites Families (10)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US3342687A (en) * 1964-06-25 1967-09-19 Colgate Palmolive Co Oral preparation
US3420817A (en) * 1966-12-06 1969-01-07 Hoffmann La Roche 4,1,5-benzoxadiazocin-2-ons and processes for preparing same
US6372438B1 (en) * 1988-02-02 2002-04-16 The Regents Of The University Of California Human platelet-derived growth factor receptors
KR100197892B1 (ko) * 1994-09-09 1999-06-15 남창우 신규한 페닐알킬아미노 카바메이트 화합물과 그의 제조방법
KR0173862B1 (ko) * 1995-02-11 1999-04-01 조규향 O-카바모일-(d)-페닐알라닌올 화합물과 그의 약제학적으로 유용한 염 및 이들의 제조방법
US5756817C1 (en) * 1995-02-11 2001-04-17 Sk Corp O-carbamoyl-phenylananinol compounds their pharmaceutically useful salts and process for preparing the same
KR0173863B1 (ko) * 1995-04-10 1999-04-01 조규향 페닐에 치환체가 있는 o-카바모일-페닐알라닌올 화합물과 그의 약제학적으로 유용한 염 및 이들의 제조방법
CN1076016C (zh) * 1996-10-10 2001-12-12 Sk株式会社 O－氨基甲酰基－苯丙胺醇化合物、其药学上有用的盐和它们的制备方法
US20020151543A1 (en) * 1998-05-28 2002-10-17 Sepracor Inc. Compositions and methods employing R (-) fluoxetine and other active ingredients
EP1313474A2 (en) * 2000-08-28 2003-05-28 Synthon B.V. Paroxetine compositions and processes for making the same

Also Published As

Publication number Publication date
BRPI0719275A2 (pt) 2014-04-29
KR20090082213A (ko) 2009-07-29
IL198145A0 (en) 2009-12-24
CN101557804A (zh) 2009-10-14
GT200900082A (es) 2010-02-24
NI200900053A (es) 2010-02-01
AU2007313017A1 (en) 2008-04-24
EA200970377A1 (ru) 2009-10-30
JP2010506845A (ja) 2010-03-04
CR10794A (es) 2009-09-29
WO2008048801A3 (en) 2008-06-05
SV2009003221A (es) 2010-04-15
EP2079449A2 (en) 2009-07-22
CO6180500A2 (es) 2010-07-19
MX2009003926A (es) 2009-06-26
WO2008048801A2 (en) 2008-04-24
US20080090902A1 (en) 2008-04-17
ZA200903283B (en) 2010-07-28
CA2673487A1 (en) 2008-04-24

Similar Documents

Publication Publication Date Title
NO20091530L (no) Fenylalkylaminokarbamat preparater
NO20091492L (no) Fenylalkylkarbamatsammensetninger
BRPI0909064A2 (pt) revestimento hidrofílico
CL2007003540A1 (es) Compuestos derivados de macrociclos, inhibidores de la proteasa serina de hepatitis c; procedimiento de preparacion; composicion farmaceutica que comprende a dicho compuesto; y uso del compuesto para el tratamiento de la hepatitis c.
CY1115526T1 (el) Φαρμακευτικη συνθεση η οποια περιλαμβανει πιμοβενδανη
ATE479687T1 (de) Kinaseinhibitoren
NO20071077L (no) Fosfonatanaloger til HIV-inhibitorforbindelser
ECSP099529A (es) Inhibidores de cinasa mapk/erk
BRPI0720569B8 (pt) compostos de tetraciclina substituída e uso dos ditos compostos para o tratamento de uma infecção bacteriana, viral ou parasitária
BRPI0713349A2 (pt) Inibidores de proteína tirosina fosfatase humana e métodos de utilização
ECSP088367A (es) Derivados de bifenilo y su uso en el tratamiento de la hepatitis c
DK1861100T3 (da) 3,11B-cis-dihydrotetrabenazin til behandling af en profilerativ sygdom eller en inflammation
NZ600271A (en) Lyophilization methods, compositions, and kits
BR112013001632A2 (pt) composto, composição farmacêutica, método de inibir uma atividade uma jak quinase in vitro, uso de um composto, ou da composição farmacêutica, e, método de fabricar um composto
AR064955A1 (es) Composicion y metodo para estabilizar ingredientes sensibles
NO20060964L (no) Farmasoytiske sammensetninger med midifisert frigjoring av modafinil
NO20082547L (no) Orale formuleringer omfattende tigecycline
CO5601045A2 (es) Procedimiento para la fabricacion de compuestos organicos
NO20055612L (no) Anti-inflammatoriske fosfonatforbindelser
NO20060896L (no) Alfa-aminoamidderivater nyttige som antiinflammatoriske midler
DE602005007765D1 (de) Neue indol- oder benzimidazol-derivate
CR9391A (es) Derivados de indanil-piperazinas, su procedimiento de preparacion y las composiciones farmaceuticas que los contienen
SV2006002220A (es) Derivados de alquiliden-tetrahidronaftaleno, procedimiento para su preparacion y su uso como antiinflamatorios ref. p-sv-78.836/cd
DE602006014001D1 (de) Herstellung von 2-aminothiazol-5-carbonsäurederivaten
CL2012002543A1 (es) Composicion endoparasiticida que comprende una combinacion de un compuesto de formula (i) derivado de amidoacetonitrilo y abamectina; y su uso para el control de endoparasitos, en particular helmintos.

Legal Events

Date Code Title Description
RE Reestablishment of rights (par. 72 patents act)
FC2A Withdrawal, rejection or dismissal of laid open patent application